Creative Biolabs Sets New Standards in Antibody Engineering & Therapeutics
New York, USA – December 20, 2023 – As the recent Antibody Engineering & Therapeutics US 2023 conference drew its curtain down, Creative Biolabs accomplished another exhibition of splendor in 2023, when a group of scientists showcased their innovative antibody products and custom antibody discovery services.
Hi-Affi™ recombinant antibodies, a flagship product offered by Creative Biolabs, garnered significant attention at the conference.
“Leveraging cutting-edge technology, we have developed a proprietary platform with optimized library construction and screening processes to enable the efficient and high-yield production of high-quality recombinant antibodies for a wide range of subjects, like model organism antibodies, rabbit monoclonal antibodies, and chicken IgY antibodies. These antibodies exhibit superior binding affinity, specificity, stability, and scalability, making them ideal for various medical and industrial research purposes.” According to a delegate from Creative Biolabs.
Creative Biolabs’ therapeutic antibody portfolio was also a highlight of the conference, which mainly consists of chimeric, human, humanized, rodent, and engineered antibodies developed to attack specific cells or proteins for the treatment of a wide variety of diseases, including immune disorders, cancers, and infections.
Furthermore, Creative Biolabs’ custom antibody development also received attention from conference attendees.
“We have a complete service pipeline for custom polyclonal and monoclonal antibody production, from gene expression or peptide synthesis to antibody purification and labeling, to meet the unique needs of researchers and pharmaceutical companies.” Noted the delegate.
During the conference, Creative Biolabs also presented several case studies highlighting successful collaborations and projects, demonstrating their ability to deliver innovative solutions and overcome complex challenges in antibody engineering and therapeutics.
“We are thrilled to have the opportunity to once again showcase our cutting-edge advancements in antibody discovery at AET US 2023,” added the delegate. “Our Hi-Affi™ recombinant antibodies, therapeutic antibodies, and custom antibody services have attracted considerable interest and praise from industry experts, reaffirming our position in the field.”
For more information about Creative Biolabs’ Hi-Affi™ recombinant antibodies, therapeutic antibodies, and custom antibody services, visit: https://www.creative-biolabs.com.
Overview
Creative Biolabs sets new standards in antibody discovery and engineering, and their outstanding performance at the Antibody Engineering & Therapeutics US 2023 conference solidifies their position as a leader in the field, leaving a lasting impact on attendees. As they continue to innovate and collaborate, the company is poised to make significant contributions to the advancement of medical and industrial research.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com
